+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Pulmonary arterial hypertension in patients treated by dasatinib



Pulmonary arterial hypertension in patients treated by dasatinib



Circulation 125(17): 2128-2137



The French pulmonary hypertension (PH) registry allows the survey of epidemiological trends. Isolated cases of precapillary PH have been reported in patients who have chronic myelogenous leukemia treated with the tyrosine kinase inhibitor dasatinib. This study was designed to describe incident cases of dasatinib-associated PH reported in the French PH registry. From the approval of dasatinib (November 2006) to September 30, 2010, 9 incident cases treated by dasatinib at the time of PH diagnosis were identified. At diagnosis, patients had moderate to severe precapillary PH with functional and hemodynamic impairment. No other incident PH cases were exposed to other tyrosine kinase inhibitors at the time of PH diagnosis. Clinical, functional, or hemodynamic improvements were observed within 4 months of dasatinib discontinuation in all but 1 patient. Three patients required PH treatment with endothelin receptor antagonist (n=2) or calcium channel blocker (n=1). After a median follow-up of 9 months (min-max 3-36), the majority of patients did not demonstrate complete clinical and hemodynamic recovery, and no patients reached a normal value of mean pulmonary artery pressure (≤20 mm Hg). Two patients (22%) died at follow-up (1 of unexplained sudden death and 1 of cardiac failure in the context of septicemia, respectively, 8 and 12 months after dasatinib withdrawal). The lowest estimate of incident PH occurring in patients exposed to dasatinib in France was 0.45%. Dasatinib may induce severe precapillary PH fulfilling the criteria of pulmonary arterial hypertension, thus suggesting a direct and specific effect of dasatinib on pulmonary vessels. Improvement is usually observed after withdrawal of dasatinib.

(PDF emailed within 0-6 h: $19.90)

Accession: 036392648

Download citation: RISBibTeXText

PMID: 22451584

DOI: 10.1161/CIRCULATIONAHA.111.079921


Related references

Pulmonary arterial hypertension in a patient treated with dasatinib: a case report. Journal of Medical Case Reports 11(1): 362, 2018

Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy. Case Reports in Cardiology 2018: 3895197, 2018

Rapid-onset pulmonary arterial hypertension in a patient with acute lymphoblastic leukemia treated with dasatinib. Herz 38(8): 931-933, 2014

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. American Journal of Hematology 90(11): 1060-1064, 2016

Long-term Outcomes of Patients With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease as Compared With Idiopathic or Heritable Pulmonary Arterial Hypertension Treated With Tadalafil. Chest Journal 140(4): 734a-734b, 2011

Comparative analysis of pulmonary hypertension in patients treated with imatinib, nilotinib and dasatinib. British Journal of Haematology 177(4): 578-587, 2017

Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension. Pulmonary Circulation 7(4): 803-807, 2017

First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension. European Respiratory Journal 51(3), 2018

Dasatinib-induced pulmonary arterial hypertension. British Journal of Clinical Pharmacology 84(5): 835-845, 2018

Dasatinib: pulmonary arterial hypertension. French data. Prescrire International 20(120): 241-241, 2011

Reversible dasatinib-related pulmonary arterial hypertension in a CML patient. Japanese Journal of Clinical Hematology 57(5): 618-623, 2016

Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. European Respiratory Journal 42(3): 869-870, 2014

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia. Cancer Research and Treatment 47(4): 937-942, 2017

Dasatinib-induced pulmonary arterial hypertension - A rare late complication. Journal of Oncology Pharmacy Practice 2018: 1078155217753740, 2018

Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography. Kaohsiung Journal of Medical Sciences 31(3): 165-166, 2015